Varenicline is a potent partial agonist at α6β2*nicotinic acetylcholine receptors in rat and monkey striatum

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 327-334

  Bordia, Tanuja ^a   Hrachova, Maya ^a   Chin, Matthew ^a   McIntosh, J Michael ^b   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6BETA2; PARTIAL AGONIST; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONCENTRATION RESPONSE; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HAPLORHINI; MALE; NEUROMODULATION; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR AFFINITY; SMOKING; SMOKING CESSATION; SYNAPTOSOME; TOBACCO DEPENDENCE;

ANIMALS; BENZAZEPINES; CORPUS STRIATUM; DOPAMINE; MALE; NICOTINE; PROTEIN BINDING; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SAIMIRI; SMOKING CESSATION; SYNAPTOSOMES;

EID: 84864146244     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194852     Document Type: Article

References (61)

1. Anderson DJ, Malysz J, Grønlien JH, El Kouhen R, Håkerud M, Wetterstrand C, Briggs CA, and Gopalakrishnan M (2009) Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity α4β2 subunit combination. Biochem Pharmacol 78:844-851.
2. Artymyshyn R, Smith A, and Wolfe BB (1990) The use of 3H standards in 125I autoradiography. J Neurosci Methods 32:185-192.
3. Barik J and Wonnacott S (2009) Molecular and cellular mechanisms of action of nicotine in the CNS. Handb Exp Pharmacol 192:173-207.
4. Benowitz NL (2010) Nicotine addiction. N Engl J Med 362:2295-2303.
5. Biala G, Staniak N, and Budzynska B (2010) Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedebergs Arch Pharmacol 381:361-370.
6. Bordia T, Campos C, McIntosh JM, and Quik M (2010) Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 333:929-938.
7. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, Karver SB, and Small BJ (2011) Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berl) 218:391-403.
8. Brody AL, Mandelkern MA, Costello MR, Abrams AL, Scheibal D, Farahi J, London ED, Olmstead RE, Rose JE, and Mukhin AG (2009) Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol 12:305-316.
9. Brunzell DH, Boschen KE, Hendrick ES, Beardsley PM, and McIntosh JM (2010) α-Conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine. Neuropsychopharmacology 35:665-673.
10. Buccafusco JJ, Beach JW, and Terry AV Jr (2009) Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328:364-370.
11. Changeux JP (2010) Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11:389-401.
12. Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, Shaffer CL, Lowe J, Rollema H, and Bartlett SE (2011) Partial agonists of the α3β4*neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 36:603-615.
13. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, et al. (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477. (Pubitemid 40664098)
14. Corrigall WA, Coen KM, and Adamson KL (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653:278-284. (Pubitemid 24252850)
15. Corrigall WA, Franklin KB, Coen KM, and Clarke PB (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107:285-289.
16. Dani JA and Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699-729.
17. De Biasi M and Dani JA (2011) Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 34:105-130.
18. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, and Evins AE (2012) Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl) 219:25-34.
19. Dwoskin LP and Bardo MT (2009) Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse. Neuropsychopharmacology 34:244-246.
20. Exley R, Clements MA, Hartung H, McIntosh JM, and Cragg SJ (2008) α6-Containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 33:2158-2166. (Pubitemid 351992087)
21. George O, Lloyd A, Carroll FI, Damaj MI, and Koob GF (2011) Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology (Berl) 213:715-722.
22. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, et al. (2006) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47-55.
23. Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, et al. (2010) Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area α6β2*receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 30:5311-5325.
24. Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, et al. (2010) Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotine acetylcholine receptors. Neuropharmacology 58:1054-1066.
25. Grady SR, Wageman CR, Patzlaff NE, and Marks MJ (2012) Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include α5 or α6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology 62:1935-1943.
26. Hatsukami DK, Stead LF, and Gupta PC (2008) Tobacco addiction. Lancet 371:2027-2038. (Pubitemid 351799860)
27. Huang LZ, Grady SR, and Quik M (2011) Nicotine reduces L-DOPA-induced dyskinesias by acting at β2 nicotinic receptors. J Pharmacol Exp Ther 338:932-941.
28. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
29. Jackson KJ, McIntosh JM, Brunzell DH, Sanjakdar SS, and Damaj MI (2009) The role of α6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J Pharmacol Exp Ther 331:547-554.
30. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, and Varenicline Phase 3 Study Group (2006) Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63.
31. Kuryatov A and Lindstrom J (2011) Expression of functional human α6β2β3*acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers. Mol Pharmacol 79:126-140.
32. Lotfipour S, Mandelkern M, Alvarez-Estrada M, and Brody AL (2012) A single administration of low-dose varenicline saturates α4β2(*) nicotinic acetylcholine receptors in the human brain. Neuropsychopharmacology 37:1738-1748.
33. Lummis SC, Thompson AJ, Bencherif M, and Lester HA (2011) Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther 339:125-131.
34. Maloku E, Kadriu B, Zhubi A, Dong E, Pibiri F, Satta R, and Guidotti A (2011) Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons. Neuropsychopharmacology 36:1366-1374.
35. Mao D and McGehee DS (2010) Nicotine and behavioral sensitization. J Mol Neurosci 40:154-163.
36. Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champtiaux N, Zoli M, et al. (2003) Effects of nicotine in the dopaminergic system of mice lacking the α4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17:1329-1337. (Pubitemid 36560833)
37. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, et al. (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436:103-107. (Pubitemid 40966193)
38. McCallum SE, Parameswaran N, Bordia T, McIntosh JM, Grady SR, and Quik M (2005) Decrease in α3*/α6*nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol Pharmacol 68:737-746. (Pubitemid 41206027)
39. McCallum SE, Parameswaran N, Perez XA, Bao S, McIntosh JM, Grady SR, and Quik M (2006) Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J Neurochem 96:960-972.
40. McNeil JJ, Piccenna L, and Ioannides-Demos LL (2010) Smoking cessation-recent advances. Cardiovasc Drugs Ther 24:359-367.
41. Meyer EL, Yoshikami D, and McIntosh JM (2008) The neuronal nicotinic acetylcholine receptors alpha 4*and alpha 6*differentially modulate dopamine release in mouse striatal slices. J Neurochem 105:1761-1769. (Pubitemid 351678494)
42. Mihalak KB, Carroll FI, and Luetje CW (2006) Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805. (Pubitemid 44268437)
43. Mineur YS and Picciotto MR (2010) Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31:580-586.
44. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, and Singh S (2011) Suicidal behavior and depression in smoking cessation treatments. PLoS One 6:e27016.
45. O'Connor EC, Parker D, Rollema H, and Mead AN (2010) The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine selfadministration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) 208:365-376.
46. Ortiz NC, O'Neill HC, Marks MJ and Grady SR (2012) Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR- mediated responses in mice in vivo. Nicotine Tob Res 14:711-719.
47. Perez XA, Bordia T, McIntosh JM, Grady SR, and Quik M (2008) Long-term nicotine treatment differentially regulates striatal α6α4β 2*and α6(nonα4)β2*nAChR expression and function. Mol Pharmacol 74:844-853.
48. Perez XA, Ly J, McIntosh JM, and MQ (2011) Chronic nicotine exposure depresses dopaminergic function in nonhuman primate nucleus accumbens, at the Nicotinic Acetylcholine Receptors: Wellcome Trust Scientific Conference; 2011 May 18-21; Cambridge, UK. Wellcome Trust, London, UK.
49. Picciotto MR, Addy NA, Mineur YS, and Brunzell DH (2008) It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84:329-342.
50. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, and Changeux JP (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177. (Pubitemid 28092475)
51. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U, and Fratta W (2008) Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 28:12318-12327.
52. 125I-α- conotoxin MII binding sites to nigrostriatal damage in monkey. J Neurosci 21:5494-5500.
53. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, and Grady SR (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63:1169-1179. (Pubitemid 36529935)
54. Raupach T and van Schayck CP (2011) Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 25:371-382.
55. 2(*) nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in β2 knock-out mice with selective re-expression of the β2 subunit in the ventral tegmental area. Neuropharmacology 58:346-350.
56. 2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316-325.
57. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, et al. (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:660-668.
58. 2+ transient generation in IMR-32 neuroblastoma cells. Neurochem Int 57:269-277.
59. Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, and Foulds J (2011) Varenicline for tobacco dependence: panacea or plight? Expert Opin Pharmacother 12:1799-1812.
60. Wise RA (2009) Roles for nigrostriatal-not just mesocorticolimbic- dopamine in reward and addiction. Trends Neurosci 32:517-524.
61. Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, and Dwoskin LP (2011) bPiDI: a novel selective α6β2*nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol 163:346-357.